Medications for the treatment of narcolepsy

Bibliography

• DAHLITZ M, PARKES JD: Sleep paralysis. Lancet (1993) 341:406–407.
   PubMed Web of Science ®Google Scholar
• GUILLEMINAULT C, RAYNAL D, TAKAHASHI S, CARSKADON M, DEMENT W: Evaluation of short-term and long term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neural. Scandinav. (1976) 54(1):71–87.
   PubMed Web of Science ®Google Scholar
• NISHINO S, MIGNOT E: Pharmacological aspects of human and canine narcolepsy. Prog. Neurobial. (1997) 52(1):27–78.
   PubMed Web of Science ®Google Scholar
• BALLIARD, BESSET A, CADILHAC J: Clinical and polygraphic development of narcolepsy. In: Guillemenault: Sleep/Wake Disorders. (1993):171–185.
   Google Scholar
• MONTPLAISIR J, BILLIARD M, TAKAHASHI S, BELL IR, GUILLEMINAULT C, DEMENT WC: Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption. Biol. Psychiatry (1978) 13(1):73–89.
   PubMed Web of Science ®Google Scholar
• International Classification of Sleep Disorders (ICSD): Diagnostic and Coding Diagnostic Classification Steering Committee (Thorpy MJ, chairman). American Sleep Disorders Association. Narcolepsy (1990) 347:38–43.
   Google Scholar
• HONDA Y: Clinical features of narcolepsy: Japanese experience in HLA in narcolepsy. Berlin (1988):24–57.
   Google Scholar
• GELB M, GUILLEMINAULT C, KRAEMER H et al.: Stability of cataplexy over several months-information for the design of therapeutic trial. Sleep (1994) 17(3):265–273.
   PubMed Web of Science ®Google Scholar
• ••Original study demonstrating validity andreliability of patient rated cataplexy assessment diaries in monitoring treatment outcomes.
   Google Scholar
• BASSETTI C, ALDRICH MS: Narcolepsy. Neurologic Clinics (1996) 14(3):545–571.
   PubMed Web of Science ®Google Scholar
• DEMENT WC, CARSKADON MA, LEY R: The prevalence of narcolepsy. Sleep Res. (1973) 2:147.
   Web of Science ®Google Scholar
• HUBLIN C, KAPRIO J, PARTINEN M et al.: The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort. Ann. NeuraL (1994) 35:709–716.
   PubMed Web of Science ®Google Scholar
• MIGNOT E: Genetic and familial aspects of narcolepsy. Neurology (1998) 50(Suppl. 1):S16–S22.
   PubMedGoogle Scholar
• SOLOMON P: Narcolepsy in Negroes. Des. Nerv. Sys. (1945):179–183.
   Google Scholar
• OHAYON MM, PRIEST RG, CAULETM, GUILLEMINAULT C: Hypnagogic and hypnopompic hallucinations: pathological phenomena? Br. J. Psychiatry (1996) 169:459–467.
   PubMed Web of Science ®Google Scholar
• GOSWANI, POLACK, COHEN, THORPY, KOVEY: Psychosocial aspects of narcolepsy. Loss Grief Care (1992) 5:1–203.
   Google Scholar
• BROUGHTON R, GUBERMAN A, ROBERTS J: Comparison of the psychosocial effects of epilepsy and narcolepsy/cataplexy: a controlled study. Epilepsia (1984) 25(4):423–433.
   PubMed Web of Science ®Google Scholar
• MITLER MM, SHAFOR R, HAJDUKOVICH R, TIMMS RM, BROWNMAN CP: Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep (1986) 9(1):260–264.
   PubMed Web of Science ®Google Scholar
• MITLER MM, HAJDUKOVICH R: Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep (1991) 14(3):218–220.
   PubMed Web of Science ®Google Scholar
• ROGERS AE, ALDRICH MS, CARUSO CC: Patterns of sleep and wakefulness in treated narcoleptic subjects. Sleep (1994) 17(7):590–597.
   PubMed Web of Science ®Google Scholar
• ROGERS AE, ALDRICH MS, BERRIOS AM, ROSENBERG RS: Compliance with stimulant medications in patients with narcolepsy. Sleep (1997) 20(1):28–33.
   Google Scholar
• YOSS RE, DALY DD: Treatment of narcolepsy with Ritalin. Neurology (1959) 9:171–173.
   PubMed Web of Science ®Google Scholar
• PARKES JD, BARAITSER M, MARSDEN CD: Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neural. Scand. (1975) 52:337–353.
   PubMed Web of Science ®Google Scholar
• WISOR JP, NISHINO S, SORA I et al.: Dopaminergic role in stimulant-induced wakefulness. J. Neurosci. (2001) 21(5):1787–1794.
   PubMed Web of Science ®Google Scholar
• ••First study demonstrating putativedopaminergic role of modafinil in promoting wakefulness.
   Google Scholar
• MIGNOT E, RENAUD A, NISHINO S et al.: Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (1993) 113:76–82.
   PubMed Web of Science ®Google Scholar
• NISHINO S, ARRIGONI J, SHELTON J et al.: Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep (1993) 17:706–712.
   Google Scholar
• NISHINO S, MIGNOT E: Pharmacological aspects of human and canine narcolepsy. Prog. Neurobial. (1997) 52:27–78.
   PubMed Web of Science ®Google Scholar
• NISHINO S, MAO J,SAMPATHKUMARAN R, SHELTON J, MIGNOT E: Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res. Online (1998) 1:49–61.
   PubMedGoogle Scholar
• LIN L, FARACO J, LI R et al.: The sleepdisorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell (1999) 98:365–376.
   PubMed Web of Science ®Google Scholar
• CHEMELLI RM, WILLIE JT, SINTON CM et al.: Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell (1999) 98(4):437–451.
   PubMed Web of Science ®Google Scholar
• PEYRON C, FARACO J, ROGERS W et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. (2000) 6(9):991–997.
   PubMed Web of Science ®Google Scholar
• ••First report of hypocretin deficiency orcomplete absence in brains of deceased narcoleptics.
   Google Scholar
• SIEGEL JM: Narcolepsy: although people with the disorder do not fall face-first into their soup as in the movies, narcolepsy is still a mysterious disease. But science has new leads. Sci. Am. (2000):76–81.
   Google Scholar
• NISHINO S, RIPLEY B, OVEREEM S, LAMMERS GJ, MIGNOT E: Hypocretin (orexin) deficiency in human narcolepsy. Lancet (2000) 1:355(9197):39–40.
   PubMed Web of Science ®Google Scholar
• •• First report of reduced levels or absence ofhypocretin in CSF of human narcoleptics.
   Google Scholar
• GUILLEMINAULT C, CARSKADON M, DEMENT WC: On the treatment of REM narcolepsy. Arch. Neural. (1974) 30:90–93.
   PubMed Web of Science ®Google Scholar
• National Sleep Foundation (NSF) Data on file.
   Google Scholar